ABSTRACT
Falsified, counterfeit and adulterated medicines are an endemic problem worldwide that results in both monetary and health-related losses. Developing fast and reliable methods that are able to present a timely result based on the drug's spectral profile is an effort that is sure to benefit those involved in the whole distribution chain. We propose herein a Laser Desorption/Ionization imaging-based method that provides simple and minimal sample preparation; this method is capable of providing specific markers that characterize adulterations, using as proof of concept one of the most adulterated drug products for oral use, sildenafil. Our approach is able to provide quality markers, which can be applied in the fast screening of any product within the same molecular class. This same strategy may be a useful alternative to provide accurate measurements with high specificity for unraveling contaminants and/or byproducts in virtually any given pharmaceutical product.
Subject(s)
Drug Compounding , Sildenafil Citrate/analysis , Humans , Molecular Conformation , Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationABSTRACT
Durante el mes de marzo de 2004, un panel de expertos y diversas autoridades nacionales de la salud pública, reunidos en la Patagonia argentina, generaron este primer documento sobre la utilización de la vacunación antigripal como parte de la estrategia médica en la prevención de las enfermedades cardiovasculares. Este grupo analizó el cuerpo de evidencia actual sobre el tema, así como las recomendaciones internacionales, tanto de la Asociación Panamericana de la Salud como de la Organización Mundial de la Salud, para la indicación de esta estrategia farmacológica. Este testimonio refleja la posición actual de todas estas partes, así como una interesante sugerencia a la comunidad médica en referencia a la actitud que se debe seguir en un futuro próximo (AU)
In March 2004, in the Patagonia, Argentina, a group of experts including national authorities, analysed the body of evidence related to anti-flu vaccination in the framework of primary and secondary prevention in ischemic heart disease. The rationale for using this pharmacological strategy, including the recommendation and suggestions given by the Pan-American Health Organization and the World Heart Organization, were deeply discussed during the meeting. The testimony is written in the present manuscript, including a critical suggestion to the medical community for the up-coming future (AU)
